Episode Details

Disc Medicine, Inc. (IRON) Q2 2026 — Reported before the open on July 30 (calendar Q2 ended June 30, 2026). There is no revenue line: R&D $46.9M (+1.3%), SG&A $18.1M (+20.2%), total operating expenses $65.1M, net loss $59.5M vs $55.2M, loss per share $(1.54) vs $(1.58) on 38.69M weighted shares. Cash, equivalents and marketable securities $717.7M, runway guided into 2029. The stock closed $73.67 on July 29, rose 7.5% to $79.21 on the print, and finished July 31 at $77.00. The line nobody printed: first-half cash used in operations was $106.4M, up 19.2% from $89.3M — the burn GREW after February's restructuring. Cash fell only $73.4M because $30.0M of the $34.0M of financing was a drawdown on the Hercules term loan. Part of the comforting cash pile is borrowed at a floor of 8.25%, secured on every asset except the intellectual property. THE CALL: AVOID (3/5, PRICED FOR A TRIAL THAT HAS NOT READ OUT) — base-case value ~$45.0 vs ~$77.0 today. KEY METRICS: - CALL: AVOID 3/5 — fair value ~$45 vs $77.00 (-42%). No revenue means no DCF, so we use a scenario tree on 38.84M economic shares (38.39M common at July 23 plus 445,422 pre-funded warrants). BEAR 40%: APOLLO misses the sunlight co-primary, leaving $654M net cash plus two mid-stage antibodies = $25. BASE 45%: APOLLO hits, bitopertin approved mid-2027, ~$700M peak sales = $50. BULL 15%: APOLLO hits clean AND selcodebart and DISC-3405 deliver = $82. Weighted at an 11% discount rate = $45 ($52 at 9%, $39 at 13%). STREET: Buy — 11 buy / 0 hold / 0 sell, 11 analysts; average target ~$101.60, range $85-$125 (Morgan Stanley $85 Overweight, Stifel $94, H.C. Wainwright $118). We DIFFER and are far more CAUTIOUS. - THE PRINT — THERE IS NO REVENUE LINE: Disc has never recorded a dollar of revenue. Q2 2026 R&D $46.933M vs $46.319M (+1.3%, flat only because more selcodebart and DISC-3405 spend offset less bitopertin manufacturing and a $10.0M milestone in the comparable quarter); SG&A $18.142M vs $15.091M (+20.2%); total operating expenses $65.075M; other income $5.612M (interest on the cash, net of loan interest); net loss $59.532M vs $55.247M; loss per share $(1.54). First half: R&D $92.837M, SG&A $41.762M, net loss $123.036M, $(3.19) per share. Accumulated deficit $633.2M against $1,279.0M of paid-in capital. - WHAT THE FDA ACTUALLY SAID (the whole thesis): the February 13, 2026 Complete Response Letter did NOT dispute the chemistry. The FDA agreed AURORA and BEACON showed bitopertin significantly lowers whole-blood metal-free PPIX (-40.7% at 60mg vs +8.0% for placebo) and conceded strong mechanistic and biological plausibility for the biomarker. It rejected the accelerated-approval filing because the trials 'did not show evidence of association' between percent change in PPIX and the sunlight-exposure endpoints. In AURORA, time in sunlight was a PRE-SPECIFIED KEY SECONDARY endpoint and it MISSED statistical significance on a strong placebo response; only a post hoc MMRM re-analysis was nominally significant (+7.1h p=0.026 at 20mg, +8.0h p=0.013 at 60mg). The Phase 3 APOLLO trial reading out in Q4 2026 carries that same endpoint as a CO-PRIMARY alongside PPIX. The endpoint that already missed once is now one bitopertin must beat outright. - THE BURN GREW AFTER THE RESTRUCTURING: H1 cash used in operations $106.437M vs $89.294M (+19.2%). Cash and marketable securities fell only $73.4M ($791.152M to $717.746M) because financing contributed $34.032M — of which $29.979M was debt, not equity. Q2 opex of $65.075M annualises near $260M. Thirteen days after the CRL, on February 26, the board cut roughly 20% of the workforce, a reduction the 8-K says 'primarily reflects focused workforce reductions among the Company's commercial functions'. H1 SG&A had risen $14.5M YoY, $12.6M of it personnel, explicitly for 'developing our commercialization capabilities'. SG&A then fell from $23.620M in Q1 to $18.142M in Q2, down 23% sequentially. The 'runway into 2029' is therefore computed on a company that is